The IJTLD
The IJTLD is the leading peer-reviewed journal dedicated to lung health worldwide.
We welcome submissions on basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
Public Health Action
Public Health Action aims to disseminate the latest operational research on health systems, public health and disease control.
We have recently expanded the scope of PHA to provide coverage of relevant areas of the UN's Sustainable Development Goals (SDGs).
IJTLD Open
Launched in January 2024, IJTLD Open is The Union's new Open Access journal for the latest research on TB and lung diseases including asthma, COVID-19 and COPD.
We welcome submissions on the development of diagnostics and treatments for the prevention, management and control of respiratory diseases.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe
Ahead of World TB Day, we present an article that assesses the burden of multimorbidity and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe
Evaluating disability, comorbidities and risk factors after TB treatment: an 18–24 month follow-up in China
Ahead of World TB Day, we present an article that assesses disability, comorbidities and risk factors after TB treatment in China.
A year in review – evaluating the launch of IJTLD OPEN
An Editorial in a forthcoming issue of IJTLD OPEN describes how open access has driven a dramatic increase in visibility.
Loss to follow-up among adults with drug-resistant TB in Papua New Guinea
An article in a forthcoming issue of PHA assesses the reasons for loss-to-follow-up in patients being treated for disease resistant TB.